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Background: To characterize the treatment and outcome of patients
with cervical and upper thoracic esophageal cancer, the authors
retrospectively reviewed the 11-year experience from The Univer-
sity of Texas M. D. Anderson Cancer Center.
Methods: Thirty-five patients with M0 cervical or upper thoracic
esophageal cancer and treated with concurrent chemoradiotherapy
were analyzed. Median radiation dose was 50.4 Gy (range, 24.5–
64.8) Gy delivered with 1.8-Gy daily fractions over 5.5 weeks.
Chemotherapy was 5-fluorouracil based. Response after treatment
was evaluated on the basis of radiography, biopsy, or both. The
survival rates were calculated by means of the Kaplan-Meier
method.
Results: The median follow-up for the surviving patients was 39
months. The actuarial 5-year overall survival (OS), cause-specific
survival, disease-free survival, local relapse-free survival, and dis-
tant metastasis-free survival rates were 18.6%, 27.6%, 22.4%,
47.7%, and 57.0%, respectively. Patients who received a radiation
dose of greater than or equal to 50 Gy had a higher complete
response rate than those who received less than 50 Gy (79.2% versus
27.3%; p  0.003). On multivariate analysis, radiation dose was the
only protective factor associated with the rates of OS (p  0.006),
cause-specific survival (p  0.003), and local relapse-free survival
(p  0.001); tumor stage was the only factor associated with rate of
disease-free survival (p  0.007).
Conclusion: Concurrent chemoradiotherapy is an effective treat-
ment modality for patients with cervical and upper thoracic esoph-
ageal cancer. The authors’ results suggest that a total radiation dose
of 50 to 65 Gy with a concurrent chemotherapy regimen may
improve local control and the OS rate in this rare type of esophageal
cancer.
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Concurrent chemoradiotherapy.
(J Thorac Oncol. 2006;1: 252–259)
Esophageal cancer located at the cervical and upper tho-racic area is rare, representing less than 10% of esopha-
geal cancer.1 Some believe that the biological behavior of
esophageal cancer at this location differs from those at the
mid and lower esophagus or gastroesophageal junction, be-
cause they are mostly squamous-cell histology with local
invasiveness and less prone to distant metastasis, and that
they should be treated like head and neck cancer. In one
study, a more favorable cause-specific survival was observed
in patients with upper-third tumors than in those with middle-
or lower-third tumors when treated with definitive chemora-
diotherapy.1
Treatment is challenging because of the high risk of
adjacent anatomical structure invasion, which precludes rad-
ical resection of the tumor. Even in patients with resectable
tumor, surgery is often an unacceptable option because a total
laryngectomy is usually required.2 In four studies of patients
with this type of cancer, those treated with surgery had
morbidity rates of 60 to 70%, mortality rates of 7 to 11%, and
a 5-year overall survival (OS) rate of 18 to 27%.3–6
Information on nonsurgical treatment of this tumor is
sparse because of the rarity of its occurrence. In a few
retrospective studies that focused on this subgroup of pa-
tients, concurrent chemoradiation was used as the treatment
of choice.7–12 Concurrent chemoradiotherapy has become a
standard treatment for surgically unresectable esophageal
cancer since the results of an intergroup, randomized, phase
III trial (RTOG 8501) were reported in 1999, which included
tumors of the thoracic esophagus.13 There was no information
on the location of the tumor or subgroup analysis on this
group of patients. Because so little information is available on
carcinoma at this location, we conducted a retrospective
analysis of data from patients with cervical and upper tho-
racic esophageal cancer who had been treated with concurrent
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chemoradiotherapy, with or without induction chemotherapy,
at our institution over a period of 11 years. To characterize
the treatment and outcome for this group of patients, we
analyzed the rates of clinical response, OS, cause-specific
survival (CSS), disease-free survival (DFS), local relapse-
free survival (LRFS), and distant metastasis-free survival
(DMFS). We also investigated prognostic factors, particularly
radiation dose, for the endpoints measured.
PATIENTS AND METHODS
Patient Population
From January of 1985 to December of 2001, a total of
703 patients with esophageal cancer were treated at the
Department of Radiation Oncology at The University of
Texas M. D. Anderson Cancer Center. Among them, 57
patients (8.1%) presented with a cervical or upper thoracic
tumor. The medical records of these patients were retrospec-
tively reviewed. To be included in our analysis, patients had
to meet the following criteria: newly pathologically con-
firmed cervical and upper thoracic esophageal cancer (tumor
located above the carina), no distant metastasis at presenta-
tion, and treatment with concurrent chemoradiotherapy but
without surgery. We excluded patients if they had had distant
metastases at presentation (n 10), treatment by means other
than surgery or radiotherapy (n 4), treatment with surgery
(n  3), radiotherapy that had not been completed or fol-
lowed up (n  2), treatment with radiotherapy alone (n  1),
recurrent disease (n  1), or two primary tumors both in the
cervical and lower esophagus (n 1). Thus, we included data
on 35 patients in this analysis. We received approval for this
retrospective review from our institutional review board, and
we complied with all Health Insurance Portability and Ac-
countability Act regulations.
Pretreatment Evaluations
The following pretreatment evaluations were per-
formed on the 35 patients: all had a medical history interview,
a physical examination, and laboratory studies, including
complete blood count and biochemical survey; radiographic
studies, including esophagograms (n  30 [86%]), chest
radiograph (n  34 [97%]), computed tomographic (CT)
scans of the chest (n  35 [100%]), CT scans of the neck
(n  13 [37%]), and CT scans of the abdominal and pelvic
scans (n  30 [86%]); bone scan (n  6 [17%]); and, when
needed, CT or magnetic resonance imaging scans of the brain
(n  3 [9%]). Other specific studies included esophagogas-
troduodenoscopy with biopsy (n  35 [100%]), endoscopic
ultrasound of the esophagus (n  6 [17%]), and broncho-
scopic examination with or without brushing or biopsy (n 
15 [43%]).
Chemotherapy
Various induction chemotherapy regimens had been
used: two to three cycles of 5-fluorouracil (5-FU) and cispla-
tin had been given to three patients; six cycles of 5-FU,
cisplatin, and paclitaxel had been given to one patient; two
cycles of 5-FU, carboplatin, and paclitaxel had been given to
one patient; and two cycles of paclitaxel had been given to
one patient. Concurrent chemotherapy had consisted of four
different regimens of 5-FU alone or in combination with
cisplatin, irinotecan, or carboplatin. Ten patients had received
continuous infusions of 5-FU alone (250 mg/m2) daily Mon-
day through Friday for 5 weeks, and 10 patients had received
continuous infusion of 5-FU (250 mg/m2) daily Monday
through Friday for 2 weeks (the number of weeks depended
on the duration of radiotherapy). 5-FU plus cisplatin had been
administered to 12 patients in one of the following three
different regimens: six patients had received continuous in-
fusion of 5-FU (750 mg/m2) on days 1 through 5 and days 29
through 33, with cisplatin (75 mg/m2) given on days 1 and 29;
four patients had received continuous infusion of 5-FU (1000
mg/m2) on days 1 through 4 and days 29 through 32 and
cisplatin (75 mg/m2) given on days 1 and 29; and two patients
had received continuous infusion of 5-FU (750 mg/m2) on
days 1 through 5 and days 29 through 33 and cisplatin (15
mg/m2) on days 1 to 5 and days 29 to 33. Three patients had
been treated with regimens that did not include cisplatin. One
of these had received continuous infusion of 5-FU (250
mg/m2) daily Monday through Friday and carboplatin (area
under the curve, 1.5) weekly for 5 weeks. The second of these
three patients had received continuous infusion of 5-FU (300
mg/m2) daily Monday through Friday and irinotecan (30
mg/m2) weekly for 5 weeks. The third had received carbo-
platin alone (80 mg/m2) every 3 weeks for 9 weeks.
Radiotherapy
Before January of 2000, conventional radiation tech-
niques were used. For patients who were irradiated with less
than or equal to 30 Gy, anteroposterior (AP) and posteroan-
terior (PA) fields were used. For patients who were irradiated
with greater than 40 Gy, AP and PA fields were used to
deliver a total dose of up to 40 Gy, and then oblique fields
were used to spare the spinal cord. Beginning in January of
2000, a three-dimensional conformal radiotherapy technique
was used. The initial target volume encompassed the primary
tumor, with 5-cm cephalad and caudal margins and a 2-cm
radial margin, with a field arrangement of AP  PA 
oblique. The supraclavicular and midcervical nodal region
was treated for all patients.
Typically, two fractionation schedules were used: the
“rapid-fractionation” (30 Gy given in 10 fractions within 2
weeks) and standard (46 Gy given at 1.8–2.0 Gy per
fraction daily, with five fractions administered weekly). The
rapid fractionation was used based on the principle that the
total radiation dose required to obtain a given biological
effect decreases as the dose per fraction increases. A 30-Gy
total dose of radiation given in 10 fractions was considered
radiobiologically equivalent to a standard 5.5-week (50.4
Gy/28 fractions) program with a shortened overall treatment
time. It was designed as a definitive treatment, combined with
concurrent chemotherapy for esophageal, pancreatic, and
periampullary carcinomas and used for prospective clinical
trials during the early 1990s in this institution. Radiation
therapy was primarily delivered with 18-MV photons, 6-MV
photons, or both. The total radiation dose varied from 24.5 to
64.8 Gy, with a median dose of 50.4 Gy at 1.8 Gy per
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fraction. Table 1 shows the distribution of the range of
radiation doses.
Follow-Up Evaluation
Patients had undergone the following types of evalua-
tions every 3 months for 2 years for the first 2 years and every
6 months thereafter: a physical examination, a complete
blood cell count, blood chemistry tests, esophagograms, and
chest radiography. Patients had also undergone endoscopic
examinations; esophageal biopsies; and CT scans of the
chest, neck, or abdomen, as indicated.
Response Assessment
Complete remission (CR) of the primary tumor had
been determined with endoscopy with or without biopsy, with
esophagography plus CT, or with both. A CR was defined as
the point at which all visible tumors had disappeared for 4
weeks or longer. The response of the metastatic lymph nodes
had been assessed by CT scan, and a CR was defined as the
complete disappearance of all measurable and assessable
disease for 4 weeks or longer.
Outcome Measures and Statistical Analyses
We defined relapse of the disease as any distant recur-
rence, regional lymph node recurrence, local recurrence, or
persistent disease during the follow-up period. The definition
of local relapse included local recurrence after tumor com-
plete remission, or progression of persistent disease. Distant
relapse included recurrence at any site other than those of the
primary tumor and regional lymph nodes.
Death from any cause was considered the endpoint for
OS, and death from esophageal cancer was the endpoint for
CCS. The survival analysis was performed by using the
Kaplan-Meier method, and the log-rank test was used to
compare the survival curves. The Cox proportional hazards
model was used for multivariate analyses. The time to an
event was calculated using the date of diagnosis. Pearson’s
chi-square test was used to assess measures of association in
frequency. A value of p  0.05 was considered statistically
significant.
RESULTS
Patients’ Characteristics and Treatments
Among esophageal cancer patients who were treated
with radiation therapy, 8.1% had cervical and upper esopha-
geal tumor. Patients’ ages ranged from 54 to 86 years (me-
dian, 64 years). There were 31 cases of squamous-cell carci-
noma and four cases of adenocarcinoma. The tumor stage
was distributed as follows for the 35 patients: T1N0 (n  1),
T2N0 (n  9), T3N0 (n  7), T2N1 (n  1), T4N0 (n  4),
T3N1 (n 8), T4N1 (n 3), and TxN0 (n 2). Tumor stage
for all patients was based on CT scans. Endoscopic ultra-
sound examinations were performed for tumor staging only
when the ultrasound probe could be introduced through the
lumen. The patients’ characteristics and treatments are sum-
marized in Table 2. Eleven patients received a radiation dose
of less than 50 Gy and 24 received greater than or equal to 50
Gy. There was a significantly higher percentage of patients
with greater than 10% of weight loss and higher disease stage
in the group that received less than 50 Gy.
Treatment Response
Of the 35 patients, 22 (62.9%) experienced a CR of the
primary tumor after concurrent chemoradiotherapy, three
(8.6%) had achieved a partial remission, three had achieved a
minor remission (8.6%), two had achieved stable disease
(5.7%), two had developed progressive disease (5.7%), and
three (8.6%) had nonassessable responses. Among the 22
patients with CR in the primary tumor, 14 were evaluated by
both endoscopy and radiography, seven by radiography only,
and one by endoscopy only. Of the 12 patients who had had
nodal metastases at presentation, three (25%) had achieved a
CR, one (8.3%) had developed progressive disease, and eight
(66.7%) had responses that were not assessable.
Patients who had been given a radiation dose of greater
than or equal to 50 Gy had a significantly higher primary
tumor CR rate than did those who had been given a dose of
less than 50 Gy (79.2% and 27.3%, respectively; p  0.003).
All 11 patients who had had T1 and T2 disease received a
radiation dose of greater than or equal to 50 Gy, and their
primary tumor CR rate was 81.8%. For patients who had had
T3 and T4 disease, the primary tumor CR rates were 75% in
those who had received a radiation dose of greater than or
equal to 50 Gy and 30% for those who had received less than
50 Gy; this difference was statistically significant (p 
0.035).
The effect of a CR of the primary tumor on outcome
was also analyzed. Patients who had experienced a CR had
significantly higher OS (p  0.008), CSS (p  0.002), DFS
(p  0.001), and LRFS (p  0.001) rates than did those who
did not. However, CR was not associated with DMFS (p 
0.52). Figure 1 illustrates the OS, CSS, LRFS, and DMFS
curves for patients who achieved a primary tumor CR and for
those who did not.
TABLE 1. Distribution of the Range of Radiation Total
Doses and Dose per Fraction for the 35 Patients Who Had
Cervical and Upper Thoracic Esophageal Cancer
No. of Patients Total Dose (Gy) Dose per Fraction (Gy)
1 24.5 3.5
2 30 5
7 30 3
1 46 2
2 50 2
5 50.4 1.8
1 52.2 1.8
1 54 1.8
1 57.6 1.8
5 59.4 1.8
7 60 2
1 64 2
1 64.8 1.8
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Patterns of Relapse
The median follow-up in surviving patients was 39
months (range, 3–64 months). Sixteen patients had experi-
enced a local relapse after an initial CR (n  4) or after
persistent disease in the esophagus (n  12). The median
time from diagnosis to local relapse or progression of the
persistent disease was 6 months (range, 1–14 months). Two
patients had developed regional lymph node relapse: one who
had experienced relapse in the anterior mediastinum and also
had developed a distant metastasis, and the other who had
experienced relapse in the posterior neck and also had devel-
oped persistent disease in the esophagus. Twelve patients had
developed distant metastases within 12 months of their diag-
nosis (range, 3–12 months; median, 6 months); six of those
metastases had developed in the lung; two in the lung and
bone; one in the lung, bone, and liver; one in the liver; and
two in the bone. Three of these 12 patients had developed
distant metastases with a local relapse or persistent disease,
and nine had had distant metastases without a local relapse or
persistent disease.
Survival and Prognostic Factors
The median survival time for the 35 patients was 13
months, and the actuarial 5-year rates for OS, CSS, DFS,
LRFS, and DMFS were 18.6%, 27.6%, 22.4%, 47.7%, and
57.0%, respectively. Twenty-six of the 35 patients died, 22 as
a result of esophageal cancer, three as a result of disease
unrelated to cancer, and one as a result of a second primary
tumor in the lung. Of the nine patients who had survived, six
had had no evidence of disease and three had had local or
distant disease or both.
We used 11 factors for the univariate analysis of sur-
vival rates: sex, age, weight loss, Karnofsky performance
status score, tumor location, tumor histologic type, tumor
stage, nodal stage, clinical stage, induction chemotherapy,
and radiation dose. We found that the radiation dose was the
only factor that was significantly related to OS (p  0.002)
and CSS (p  0.0009). The 5-year OS rates were 0% and
29% for patients who had received a radiation dose of less
than 50 Gy and greater than or equal to 50 Gy, respectively.
The 5-year CSS rates were 0% and 44% for patients who had
received a radiation dose of less than 50 Gy and greater than
or equal to 50 Gy, respectively. Radiation dose (p  0.03),
tumor stage (p  0.009), and clinical stage (p  0.020) were
significant factors in predicting DFS. Patients who had re-
ceived a radiation dose of greater than or equal to 50 Gy and
who had T1 or T2 disease and clinical stage I or II disease had
TABLE 2. Clinical Characteristics and Treatment for 35 Patients with Cervical and Upper Thoracic Esophageal Cancer
Characteristics No. of Patients (%) RT < 50 Gy (n  11) RT > 50 Gy (n  24) p Value
Gender
Male 24 (68.6) 8 (72.7) 16 (66.7)
Female 11 (31.4) 3 (27.3) 8 (33.3) 0.720
Age
65 yr 18 (51.4) 5 (45.5) 13 (54.2)
65 yr 17 (48.6) 6 (54.5) 11 (45.8) 0.632
Weight loss
10% 11 (31.4) 6 (54.5) 5 (20.8)
10% 24 (68.6) 5 (45.5) 19 (79.2) 0.046
Karnofsky performance status
50–70 6 (17.1) 1 (9.1) 5 (20.8)
80–100 29 (82.9) 10 (90.9) 19 (79.2) 0.392
Location
Cervical esophagus 22 (62.9) 6 (54.5) 16 (66.7)
Upper thoracic esophagus 13 (37.1) 5 (45.5) 8 (33.3) 0.491
Histologic type
Squamous-cell carcinoma 31 (88.6) 10 (90.9) 21 (87.5)
Adenocarcinoma 4 (11.4) 1 (10.1) 3 (12.5) 0.769
Tumor stage
T1 and T2 11 (33.3) 0 (0) 11 (47.8)
T3 and T4 22 (66.7) 10 (100) 12 (52.2) 0.007
Nodal stage
N0 23 (65.7) 5 (45.5) 18 (75)
N1 12 (34.3) 6 (54.5) 6 (25) 0.087
Clinical stage
I and II 18 (54.5) 2 (20) 16 (69.6)
III 15 (45.5) 8 (80) 7 (34.4) 0.009
Induction chemotherapy
Yes 6 (17.1) 3 (27.3) 3 (12.5)
No 29 (82.9) 8 (72.7) 21 (87.5) 0.282
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higher DFS rates than other patients. Radiation dose (p 
0.0001), weight loss (p  0.029), tumor stage (p  0.034),
and clinical stage (p  0.039) were significant factors in
predicting LRFS rate. Patients who had received a radiation
dose of greater than or equal to 50 Gy and had had a weight
loss of less than or equal to 10%, T1 or T2 disease, and
clinical stage I or II disease had a better LRFS rate than those
of the other patients. No factor had a significant effect on the
DMFS rate. Only one of the six patients who had received
induction chemotherapy developed a distant metastasis, com-
pared with 11 of the 29 patients who had not received it, but
the difference was not statistically significant (p  0.263).
In the multivariate analysis, radiation dose, weight loss,
tumor stage, and clinical stage were included as variables.
Radiation dose was the only factor associated with OS (p 
0.006), CSS (p  0.003), and LRFS (p  0.001). Tumor
stage was the only factor found to be associated with DFS
(p  0.007). Figure 2 shows the OS, CSS, LRFS, and DMFS
curves for patients who received radiation doses of greater
than or equal to 50 Gy and less than 50 Gy.
DISCUSSION
In this study, we found that the survival rates of patients
with cervical and upper thoracic esophageal cancer who had
received concurrent chemoradiotherapy were comparable to
the results reported in the literature (Table 3). We also found
that the OS, CSS, and LDFS rates were significantly higher in
patients who had received a radiation dose of greater than or
equal to 50 Gy than in those who had received a dose of less
than 50 Gy.
In our study, radiation dose was the only independent
factor associated with improved local control and overall
survival; however, because of the small number of patients
and the retrospective nature of this study, conclusions should
be drawn with caution.
The data to support the existence of a dose-dependent
response in esophageal cancer are not strong. Three studies
using high-dose, three-dimensional, conformal radiation ther-
apy concurrently with chemotherapy have yielded promising
results. In one study, patients with a large tumor burden (T3
or T4 primary) in the upper thoracic and midthoracic esoph-
FIGURE 1. OS, CSS, DFS, LRFS, and DMFS rates for patients who achieved CR in the primary tumor and for patients who
did not achieve CR.
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agus were given a higher dose of up to 65 Gy, and the
long-term survival was 31% at 3 years.11 In another study,
The 5-year actuarial survival rate was 55% when high-dose
radiotherapy (median, 61.2 Gy; range, 50.4 Gy/20 frac-
tions–65 Gy/33 fractions) was given for patients with cervi-
cal esophageal cancers, although the majority of patients in
this group had early-stage tumors.8 The 5-year survival of
50% was also observed in another study in which a total
radiation dose of 60 Gy was delivered to patients with
upper-third esophageal cancers.6
The only randomized dose-escalation study (Intergroup
Trial 0123) shows that increasing the radiation dose from
50.4 Gy to 64.8 Gy does not result in better local control or
survival rate among patients with esophageal cancer who
were treated with concurrent chemoradiotherapy.14 However,
seven of the 11 treatment-related deaths in the high-dose arm
FIGURE 2. OS, CSS, DFS, LRFS, and DMFS rates for patients who received a radiation dose of greater than or equal to 50 Gy
and patients who received a radiation dose of less than 50 Gy.
TABLE 3. Summary of Reports for Patients with Esophageal Cancer Treated with Concurrent Chemoradiotherapy
Reference Location
Induction
Chemotherapy
Radiation
Dose (Gy)
CR Rate
(%)
LC Rate
(%)
DM Rate
(%)
OS Rate
(%) CSS (%)
Denham et al.1 (n  35) Upper third No 60 NR 53 at 3 yr 20 at 3 yr NR 50 at 5 yr
Burmeister et al.8 (n  34) Cervical No 50.4–65 91 88% NR 55 at 5 yr NR
Stuschke et al.10 (n  17) Cervical Yes 60–66 47 33 at 3 yr 39 at 3 yr 24 at 3 yr NR
Bidoli et al.9 (n  58) Cervical and upper thoracic No 50 64 NR NR 27 at 10 yr* NR
Stuschke et al.11 (n  22) Upper and midthoracic Yes 60–65 NR 40 at 3 yr 23 at 3 yr 31 at 3 yr NR
Current study (n  35) Cervical and upper thoracic 17% yes 24.5–64.8 63 48 at 5 yr 43 at 5 yr 19 at 5 yr 28 at 5 yr
* For cervical esophageal cancer only (n  31). For upper thoracic esophageal cancer treated with nonsurgical therapy (n  27) and surgery (n  33), the 10-year OS was 6%.
NR, not reported; CR, complete remission; LC, local control; DM, distant metastatic; OS, overall survival; CSS, cause-specific survival.
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of the RTOG 94-05 trial occurred in patients who had
received 50.4 Gy or less. There was a significant prolongation
of treatment time because of breaks required for recovery
from side effects after correction for the number of radiation
treatments and a significantly lower dose of 5-FU given to
patients on the high-dose arm. The authors believed that these
factors might have contributed, at least in part, to the lack of
benefit for patients who received high-dose versus standard-
dose radiotherapy.14 The findings in the RTOG 94-05 study
warrant extensive research on methods to reduce treatment
toxicity to allow radiation dose intensification for patients
who are not considered candidates for surgery and for whom
chemoradiation is the only treatment alternative.
A pathologic CR was found in 24 to 43% of patients
treated with neoadjuvant concurrent chemoradiotherapy with
radiation doses ranging from 37 to 45.6 Gy given in various
fractions.15–17 The CR rate in our study was 63%, which is
comparable to those in other studies (47–91%) for cervical
and upper thoracic esophageal cancer treated with concurrent
chemoradiotherapy.7–9 In the 35 patients in our analyses, a
higher radiation dose was associated with a higher CR rate,
and a higher CR rate was associated with higher 5-year OS
and CSS. Because patients with an early clinical tumor stage
had all received high-dose radiation, we also performed a
dose-response analysis on patients who had had advanced
tumors and found similar results. Thus, as indicated by the
results of those previous studies and ours, it appears that the
radiation dose of 50 to 65 Gy should be used as a definitive
treatment for this patient population.
The development of distant metastasis is an obstacle to
improving the survival rate in patients with this disease.
Because 75% (nine of 12) of the distant metastases developed
in our patients who had not experienced a local relapse, a
higher radiation dose and CR in the primary tumor improved
local tumor control but failed to improve DFS because of the
higher rate of distant metastases. Theoretically, because all
the distant metastases in our patients developed within 12
months of diagnosis, induction chemotherapy or intensified
concurrent chemotherapy might be beneficial in the early
treatment of occult micrometastases. Unfortunately, however,
induction chemotherapy did not significantly reduce the num-
ber of distant metastases in our small number of patients. In
an intergroup trial (INT 0122) reported in 1999, treatment
with three cycles of induction chemotherapy (5-FU and
cisplatin) plus concurrent chemoradiotherapy (5-FU and cis-
platin plus 64.8 Gy radiation) did not appear to improve the
5-year OS rate (20%) or the distant metastasis rate (24%), and
9% of the patients died as a result of complications of
treatment.18
Newer agents than 5-FU and cisplatin that are being
used clinically or are still investigational for treating esoph-
ageal cancer are showing promise for increasing local control
and decreasing distant metastasis. Preliminary results of treat-
ments that have included paclitaxel or irinotecan are encour-
aging and have shown a pathologic CR rate of approximately
60%.19,20 The use of molecular targeting agents such as
cetuximab in combination with radiotherapy, which yielded
positive results in treating head and neck cancer,21 is being
investigated for treating esophageal cancer in combination
with cisplatin, paclitaxel, and radiotherapy in the RTOG 0436
trial. Whether these investigational approaches will result in
better responses than are achieved with the conventional
chemoradiation regimens based on 5-FU and cisplatin re-
mains to be seen.
CONCLUSION
In summary, we believe that concurrent chemoradio-
therapy is a good treatment option for patients with cervical
and upper thoracic esophageal cancer. Our results suggest
that a total radiation dose of 50 to 65 Gy with a concurrent
chemotherapy regimen may improve local control and the OS
rate in this rare type of esophageal cancer.
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